Aprea Therapeutics annual depreciation and amortization
2017
2018
2019
2020
2021
2022
2023
2024
2025
Aprea Therapeutics Depreciation & Amortization Growth & History (APRE)
Aprea Therapeutics's depreciation and amortization was $21,715 for fiscal 2025.
View full Aprea Therapeutics company overviewAprea Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $21,715 | −$603 | −2.70% |
| 2024 | 2024-12-31 | $22,318 | $15,266 | +216.48% |
| 2023 | 2023-12-31 | $7,052 | $2,649 | +60.16% |
| 2022 | 2022-12-31 | $4,403 | −$8,426 | −65.68% |
| 2021 | 2021-12-31 | $12,829 | −$16,005 | −55.51% |
| 2020 | 2020-12-31 | $28,834 | $17,708 | +159.16% |
| 2019 | 2019-12-31 | $11,126 | $2,810 | +33.79% |
| 2018 | 2018-12-31 | $8,316 | $384 | +4.84% |
| 2017 | 2017-12-31 | $7,932 | — | — |
Aprea Therapeutics quarterly depreciation and amortization
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5,746 | $318 | +5.86% |
| Q1 2026 | 2026-03-31 | $5,428 | −$1 | −0.02% |
| Q4 2025 | 2025-12-31 | $5,429 | — | — |
| Q3 2025 | 2025-09-30 | $5,429 | $0 | 0.00% |
| Q2 2025 | 2025-06-30 | $5,428 | $124 | +2.34% |
| Q1 2025 | 2025-03-31 | $5,429 | −$728 | −11.82% |
| Q3 2024 | 2024-09-30 | $5,429 | $3,997 | +279.12% |
| Q2 2024 | 2024-06-30 | $5,304 | $5,080 | +2267.86% |
| Q1 2024 | 2024-03-31 | $6,157 | $5,747 | +1401.71% |
| Q3 2023 | 2023-09-30 | $1,432 | $1,310 | +1073.77% |
| Q2 2023 | 2023-06-30 | $224 | −$3,500 | −93.98% |
| Q1 2023 | 2023-03-31 | $410 | −$2,532 | −86.06% |
| Q3 2022 | 2022-09-30 | $122 | −$3,014 | −96.11% |
| Q2 2022 | 2022-06-30 | $3,724 | $588 | +18.75% |
| Q1 2022 | 2022-03-31 | $2,942 | −$646 | −18.00% |
| Q3 2021 | 2021-09-30 | $3,136 | −$1,175 | −27.26% |
| Q2 2021 | 2021-06-30 | $3,136 | −$918 | −22.64% |
| Q1 2021 | 2021-03-31 | $3,588 | −$224 | −5.88% |
| Q3 2020 | 2020-09-30 | $4,311 | $197 | +4.79% |
| Q2 2020 | 2020-06-30 | $4,054 | $1,456 | +56.04% |
| Q1 2020 | 2020-03-31 | $3,812 | $1,671 | +78.05% |
| Q3 2019 | 2019-09-30 | $4,114 | — | — |
| Q2 2019 | 2019-06-30 | $2,598 | — | — |
| Q1 2019 | 2019-03-31 | $2,141 | — | — |
Aprea Therapeutics depreciation and amortization trends
Over the last five fiscal years, Aprea Therapeutics's depreciation and amortization decreased from $28,834 to $21,715, a change of −$7,119. The latest reported quarter, Q2 2026, shows $5,746.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aprea Therapeutics source filings ↗